ICON: Eosinophil Disorders

Hardy WR, Anderson RE: The hypereosinophilic syndromes. Ann Intern Med. 1968, 68: 1220-1229. 10.7326/0003-4819-68-6-1220. Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975, 54: 1-27. 10.1097/00005792-197501000-00001. Weller PF, Bubley GJ: The idiopathic hypereosinophilic syndrome. Blood. 1994, 83: 2759-2779. Roufosse F, Cogan E, Goldman M: The hypereosinophilic syndrome revisited. Annu Rev Med. 2003, 54: 169-184. 10.1146/annurev.med.54.101601.152431. Wilkins HJ, Crane MM, Copeland K, Williams WV: Hypereosinophilic syndrome: an update. Am J Hematol. 2005, 80: 148-157. 10.1002/ajh.20423. Simon D, Simon HU: Eosinophilic disorders. J Allergy Clin Immunol. 2007, 119: 1291-1300. 10.1016/j.jaci.2007.02.010. Simon HU, Rothenberg ME, Bochner BS, et al: Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol. 2010, 126: 45-49. 10.1016/j.jaci.2010.03.042. Valent P: Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev. 2009, 23: 157-165. 10.1016/j.blre.2009.01.001. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, et al: Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012, 130: 607-612. 10.1016/j.jaci.2012.02.019. Bain BJ, Pierre R, Imbert M, Vardiman JW, Brunning RD, et al: Chronic eosinophilic leukemia and the hypereosinophilic syndrome. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Edited by: Jaffe ES, Harris NL, Stein H, Vardiman JW. 2001, Lyon, France: IARC Press, 1: 29-31. Bain BJ, Gilliland DG, Vardiman JW, Horny HP: Chronic eosinophilic leukemia, not otherwise specified. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Edited by: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. 2008, Lyon, France: IARC Press, 2: 51-53. Bain BJ, Gilliland DG, Horny HP, Vardiman JW: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Edited by: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. 2008, Lyon, France: IARC Press, 2: 68-73. Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008, 22: 14-22. 10.1038/sj.leu.2404955. Vandenberghe P, Wlodarska I, Michaux L, et al: Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004, 18: 734-742. 10.1038/sj.leu.2403313. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C: The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol. 2008, 87: 1-10. Cross NC, Reiter A: Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol. 2008, 119: 199-206. 10.1159/000140631. Gotlib J, Cools J: Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008, 22: 1999-2010. 10.1038/leu.2008.287. Tefferi A: Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. JCellMol Med. 2009, 13: 215-237. Kay AB: The eosinophil in infection diseases. J Infect Dis. 1974, 129: 606-613. 10.1093/infdis/129.5.606. Capron M: Eosinophils and parasites. Ann Parasitol Hum Comp. 1991, 66: 41-45. Walsh SA, Creamer D: Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011, 36: 6-11. 10.1111/j.1365-2230.2010.03967.x. Kargili A, Bavbek N, Kaya A, Kosxar A, Karaaslan Y: Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases. Rheumatol Int. 2004, 24: 321-324. 10.1007/s00296-004-0469-6. Tefferi A, Patnaik MM, Pardanani A: Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006, 133: 468-492. 10.1111/j.1365-2141.2006.06038.x. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, et al: Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987, 1: 643-647. Kato M, Kephart GM, Talley NJ, et al: Eosinophil infiltration and degranulation in normal human tissue. Anat Record. 1998, 252: 418-425. 10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1. Noguchi H, Kephart GM, Colby TV, Gleich GJ: Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol. 1992, 140: 521-528. Nutman TB: Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin North Am. 2007, 27: 529-549. 10.1016/j.iac.2007.07.008. Gotlib J, Cross NC, Gilliland DG: Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006, 19: 535-569. 10.1016/j.beha.2005.07.013. Bain BJ, Fletcher SH: Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2007, 27: 377-388. 10.1016/j.iac.2007.06.001. Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, et al: Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012, 5: 157-176. 10.1586/ehm.11.81. Wimazal F, Germing U, Kundi M, Noesslinger T, Blum S, et al: Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer. 2010, 116: 2372-2381. Pardanani A, Reeder T, Li CY, Tefferi A: Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res. 2003, 27: 883-885. 10.1016/S0145-2126(03)00065-1. Böhm A, Födinger M, Wimazal F, Haas OA, Mayerhofer M, et al: Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol. 2007, 120: 192-199. 10.1016/j.jaci.2007.03.015. Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, et al: Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009, 114: 3769-3772. 10.1182/blood-2009-05-220145. Takai K, Sanada M: Hypereosinophilic syndrome evolving to acute lymphoblastic leukemia. Int J Hematol. 1991, 54: 231-239. Scales JW, McMichael A: Persistent peripheral eosinophilia and cutaneous non-Hodgkin's lymphoma: a case report and review of the literature. Cutis. 2001, 67: 67-70. Roufosse F, Cogan E, Goldman M: Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007, 27: 389-413. 10.1016/j.iac.2007.07.002. Reiter A, Sohal J, Kulkarni S, Chase A, Macdonald DH, et al: Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13) (p11;q12) myeloproliferative syndrome. Blood. 1998, 92: 1735-1742. Lowe D, Jorizzo J, Hutt MS: Tumour-associated eosinophilia: a review. J Clin Pathol. 1981, 34: 1343-1348. 10.1136/jcp.34.12.1343. Hogan SP, Rosenberg HF, Moqbel R, et al: Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008, 38: 709-750. 10.1111/j.1365-2222.2008.02958.x. Simon HU, Plötz SG, Dummer R, Blaser K: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999, 341: 1112-1120. 10.1056/NEJM199910073411503. Roufosse F, Schandené L, Sibille C, Willard-Gallo K, Kennes B, et al: Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000, 109: 540-548. 10.1046/j.1365-2141.2000.02097.x. Freymond N, Kahn JE, Legrand F, Renneville A, Cordier JF, et al: Clonal expansion of T cells in patients with eosinophilic lung disease. Allergy. 2011, 66: 1506-1508. 10.1111/j.1398-9995.2011.02697.x. Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, O'Connell EJ, et al: Episodic angioedema associated with eosinophilia. N Engl J Med. 1984, 310: 1621-1626. 10.1056/NEJM198406213102501. Butterfield JH, Leiferman KM, Abrams J, et al: Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992, 79: 688-692. Gross WL: Churg-Strauss syndrome: update on recent developments. Curr Opin Rheumatol. 2002, 14: 11-14. 10.1097/00002281-200201000-00003. Keogh KA, Specks U: Churg-Strauss syndrome. Semin Respir Crit Care Med. 2006, 27: 148-157. 10.1055/s-2006-939518. Pagnoux C, Guillevin L: Churg-Strauss syndrome: evidence for disease subtypes?. Curr Opin Rheumatol. 2010, 22: 21-28. 10.1097/BOR.0b013e328333390b. Silver RM: Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1992, 4: 851-856. Kaufman LD, Krupp LB: Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1995, 7: 560-567. 10.1097/00002281-199511000-00016. Belongia EA, Gleich GJ: The eosinophilia-myalgia syndrome revisited. J Rheumatol. 1996, 23: 1682-1685. Crane MM, Chang CM, Kobayashi MG, Weller PF: Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol. 2010, 126: 179-181. 10.1016/j.jaci.2010.03.035. Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, et al: Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Hematol Oncol. 2010, 28: 93-97. Gleich GJ: Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 2000, 105: 651-663. 10.1067/mai.2000.105712. Ackerman SJ, Bochner BS: Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am. 2007, 27: 357-375. 10.1016/j.iac.2007.07.004. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, et al: Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol. 1989, 19: 701-705. 10.1002/eji.1830190420. Kita H, Weiler DA, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ: Release of granule proteins from eosinophils cultured with IL-5. J Immunol. 1992, 149: 629-635. Yousefi S, Blaser K, Simon HU: Activation of signaling pathways and prevention of apoptosis by cytokines in eosinophils. Int Arch Allergy Immunol. 1997, 112: 9-12. 10.1159/000237424. Kahn JE, Dutoit-Lefevre V, Duban-Deweer S, Chafey P, Pottiez G, et al: Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. J Proteome Res. 2011, 10: 1468-1480. 10.1021/pr100836p. Weller PF: Eicosanoids, cytokines and other mediators elaborated by eosinophils. Eosinophils: Biological and Clinical Aspects. Edited by: Makino S, Fukuda T. 1993, Boca Raton, FL: CRC Press, 125-154. Moqbel R, Levi-Schaffer F, Kay AB: Cytokine generation by eosinophils. J Allergy Clin Immunol. 1994, 94: 1183-1188. 10.1016/0091-6749(94)90330-1. Moqbel R, Ying S, Barkans J, et al: Identification of messenger RNA for IL-4 in human eosinophils with granule localisation and release of the translated product. J Immunol. 1995, 155: 4939-4947. Kay AB, Barata L, Meng Q, Durham SR, Ying S: Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol. 1997, 113: 196-199. 10.1159/000237545. Walsh GM: Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci. 1999, 36: 453-496. 10.1080/10408369991239277. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, et al: Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol. 1989, 142: 4428-4434. Hamann KJ, Barker RL, Ten RM, Gleich GJ: The molecular biology of eosinophil granule proteins. Int Arch Allergy Appl Immunol. 1991, 94: 202-209. 10.1159/000235362. Plager DA, Stuart S, Gleich GJ: Human eosinophil granule major basic protein and its novel homolog. Allergy. 1998, 53: 33-40. Benezet-Mazuecos J, de la Fuente A, Marcos-Alberca P, Farre J: Loeffler endocarditis: what have we learned?. Am J Hematol. 2007, 82: 861-862. 10.1002/ajh.20957. Ogbogu PU, Rosing DR, Horne MK: Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007, 27: 457-475. 10.1016/j.iac.2007.07.001. Kleinfeldt T, Nienaber CA, Kische S, Akin I, Turan RG, et al: Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol. 2010, 99: 419-427. 10.1007/s00392-010-0144-8. Jeong YJ, Kim KI, Seo IJ, Lee CH, Lee KN, et al: Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. Radiographics. 2007, 27: 617-637. 10.1148/rg.273065051. Simon D, Wardlaw A, Rothenberg ME: Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol. 2010, 126: 3-13. 10.1016/j.jaci.2010.01.055. Louis R, Sele J, Henket M, Cataldo D, Bettiol J, et al: Sputum eosinophil count in a large population of patients with mild to moderate steroidnaïve asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy. 2002, 57: 907-912. 10.1034/j.1398-9995.2002.23608.x. Szefler SJ, Wenzel S, Brown R, et al: Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012, 129: S9-23. 10.1016/j.jaci.2011.12.979. Leiferman KM, Gleich GJ, Peters MS: Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007, 27: 415-441. 10.1016/j.iac.2007.07.009. Zuo L, Rothenberg ME: Gastrointestinal eosinophilia. Immunol Allergy Clin North Am. 2007, 27: 443-455. 10.1016/j.iac.2007.06.002. Lee J, Dierkhising R, Wu TT, Alexander J, Weiler C: Eosinophilic gastrointestinal disorders (EGID) with peripheral eosinophilia: a retrospective review at Mayo Clinic. Dig Dis Sci. 2011, 56: 3254-3261. 10.1007/s10620-011-1754-3. Klion A: Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med. 2009, 60: 293-306. 10.1146/annurev.med.60.062107.090340. Klion AD: How I treat hypereosinophilic syndromes. Blood. 2009, 114: 3736-3741. 10.1182/blood-2009-07-143552. Roufosse F, Weller P: Practical approach to the patient with marked hypereosinophilia. J Allergy Clin Immunol. 2010, 126: 39-44. 10.1016/j.jaci.2010.04.011. Rothenberg ME, Klion AD, Roufosse FE, et al: Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008, 358: 1215-1228. 10.1056/NEJMoa070812. Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, et al: Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol. 2010, 126: 828-835. 10.1016/j.jaci.2010.06.049. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002, 347: 481-487. 10.1056/NEJMoa020150. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003, 348: 1201-1214. 10.1056/NEJMoa025217. Pardanani A, Reeder T, Porrata LF, et al: Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003, 101: 3391-3397. 10.1182/blood-2002-10-3103. Tefferi A: Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005, 114: 52-60. 10.1159/000085562. Reiter A, Grimwade D, Cross NC: Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders. Haematologica. 2007, 92: 1153-1158. 10.3324/haematol.10328. Metzgeroth G, Walz C, Erben P, et al: Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008, 143: 707-715. 10.1111/j.1365-2141.2008.07294.x.